Based in Tampa, Florida, Virginia Pelley is a former women's magazine editor who has written health and fitness content for Men's Journal, Cosmopolitan magazine, the Chicago Tribune, ...

Strattera vs. Ritalin: What Is the Difference? Strattera and Ritalin are medicines that children and adults can take to manage symptoms of attention deficit hyperactivity disorder (ADHD). Both drugs ...

Strattera (atomoxetine) is a prescription drug that’s used to treat attention deficit hyperactivity disorder (ADHD). Strattera comes as an oral capsule. Strattera is used in adults and certain ...

Medically reviewed by Smita Patel, DO Strattera is a non-stimulant medication for ADHD that works by increasing norepinephrine in your brain.Common side effects of Strattera include dry mouth, nausea, ...

Strattera, an attention deficit hyperactivity disorder treatment manufactured by Eli Lilly, will carry a "black box" warning based on a review of earlier clinical trials that found the drug might ...

The Food and Drug Administration warned doctors Thursday about reports of suicidal thinking in some children and adolescents who are taking Strattera, a drug used to treat attention deficit ...

THE POWER of marketing can clearly be seen in the case of Strattera, Eli Lilly's new drug for attention deficit/hyperactivity disorder. The company is hoping its drug will help fill the gap left in ...

One of the main benefits touted by Lilly is that Strattera is the only ADHD drug on the market that is not a stimulant, meaning users are less likely to abuse it. The makers of Adderall and Concerta ...

Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, convinced a judge to temporarily block generic versions of its attention-deficit treatment Strattera while the company considers an ...

Strattera had $483.3 million in sales in the first three quarters of fiscal year 2004. Anthony Butler, an analyst for Lehman Brothers, predicts sales of $770 million in FY 2005 (Wall Street Journal, ...

Eli Lilly’s big-earning ADHD med Strattera has succumbed to generics. Four drugmakers won FDA green lights for their copycats Tuesday, and the competitive pressure is expected to quickly tank the ...